CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $5.55B, above the global median of $1.15B
- PositionOperating margin is 37.5%, higher than 95% of its Medical Devices peers (median 7.3%)
- Interpretations11 currently firing — 11
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.38%Below 5Y avg (0.41%)
Annual Rate
CNY 1.00Paid annual
Payout Ratio
19.7%Sustainable
Last Ex-Dividend
May 14, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
37.29BCNY5.55B · vs all stocks (USD)
Trailing P/E
37.27xvs Medical Devices peers
Revenue (TTM)
2.72BCNY405.05M · vs all stocks (USD)
Profit Margin
31.83%vs Medical Devices peers
Beta
-0.3800xvs all stocks
52-Week Change
-6.09%vs all stocks
Market Capitalization
37.29BCNY5.55B · vs all stocks (USD)
Enterprise Value
30.73BCNY4.57B · vs all stocks (USD)
Trailing P/E
37.27xvs Medical Devices peers
Forward P/E
25.60xvs Medical Devices peers
Price to Sales (TTM)
11.87xvs Medical Devices peers
Price to Book (MRQ)
10.77xvs Medical Devices peers
Enterprise to Revenue
11.28xvs Medical Devices peers
Enterprise to EBITDA
29.24xvs Medical Devices peers
Gross Margin
72.43%vs Medical Devices peers
Profit Margin
31.83%vs Medical Devices peers
Operating Margin
37.53%vs Medical Devices peers
Return on Assets (TTM)
17.96%vs Medical Devices peers
Return on Equity (TTM)
29.72%vs Medical Devices peers
Revenue (TTM)
2.72BCNY405.05M · vs all stocks (USD)
Revenue per Share (TTM)
19.35CNYUpdated Aug 21, 2026Quarterly Revenue Growth
24.80%vs Medical Devices peers
Gross Profit (TTM)
1.97BCNY293.56M · vs all stocks (USD)
EBITDA (TTM)
1.00BCNY148.95M · vs all stocks (USD)
Net Income (TTM)
866.92MCNY128.92M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
25.30%vs Medical Devices peers
Operating Cash Flow (TTM)
993.29MCNY147.71M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
367.81MCNY54.70M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.38%vs all stocks
5-Year Average Dividend Yield
0.41%vs all stocks
Payout Ratio
19.69%vs Medical Devices peers
Minority Interest (Equity)
41.68MCNYFY2025 · Dec 31, 2025Revenue
2.58BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
700.84MCNYFY2025 · Dec 31, 2025Gross Profit
1.88BCNYFY2025 · Dec 31, 2025Operating Income
944.69MCNY140.49M · vs all stocks (USD)
Pre-tax Income
936.29MCNYFY2025 · Dec 31, 2025Income Tax Expense
128.55MCNYFY2025 · Dec 31, 2025Net Income
807.74MCNYFY2025 · Dec 31, 2025EBIT
937.75MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.07BCNYFY2025 · Dec 31, 2025Research & Development
364.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
229.37MCNYFY2025 · Dec 31, 2025Other Operating Expenses
33.68MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.46MCNYFY2025 · Dec 31, 2025EPS (Basic)
5.82CNYFY2025 · Dec 31, 2025EPS (Diluted)
5.80CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
141.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
141.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
807.74MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
12.90MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
572.56MCNYFY2025 · Dec 31, 2025Free Cash Flow
287.19MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.25BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
807.74MCNYFY2025 · Dec 31, 2025Other Non-cash Items
8.45MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-120.86MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-122.77MCNYFY2025 · Dec 31, 2025Capital Expenditures
-285.37MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.74BCNYFY2025 · Dec 31, 2025Sale of Investments
2.52BCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.29MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-519.18MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
4.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-671.00KCNYFY2025 · Dec 31, 2025Common Dividends Paid
-170.27MCNYFY2025 · Dec 31, 2025Other Financing Charges
-112.80MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-279.74MCNYFY2025 · Dec 31, 2025Shares Outstanding
141.04MSharesUpdated Aug 21, 2026Float Shares
74.75MSharesUpdated Aug 21, 2026% Held by Insiders
47.54%vs all stocks
% Held by Institutions
23.72%vs all stocks
Total Cash (MRQ)
1.29BCNY191.98M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.23CNYUpdated Aug 21, 2026Total Debt (MRQ)
14.55MCNY2.16M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0048xvs Medical Devices peers
Current Ratio (MRQ)
5.20xvs Medical Devices peers
Book Value per Share (MRQ)
21.22CNYUpdated Aug 21, 2026Total Assets
3.65BCNY543.07M · vs all stocks (USD)
Total Current Assets
2.12BCNYFY2025 · Dec 31, 2025Total Liabilities
521.51MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.53BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
62.55MCNYFY2025 · Dec 31, 2025Total Current Liabilities
458.96MCNYFY2025 · Dec 31, 2025Cash
1.25BCNYFY2025 · Dec 31, 2025Cash Equivalents
18.35MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.26BCNYFY2025 · Dec 31, 2025Other Short-term Investments
250.49MCNYFY2025 · Dec 31, 2025Accounts Receivable
78.22MCNYFY2025 · Dec 31, 2025Inventory
491.96MCNYFY2025 · Dec 31, 2025Accounts Payable
60.32MCNYFY2025 · Dec 31, 2025Short-term Debt
7.83MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.70MCNYFY2025 · Dec 31, 2025Long-term Debt
11.57MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.02MCNYFY2025 · Dec 31, 2025Common Stock (Book)
141.03MCNYFY2025 · Dec 31, 2025Retained Earnings
2.29BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.13BCNY465.51M · vs all stocks (USD)
Treasury Stock
99.94MCNYFY2025 · Dec 31, 202552-Week Low
176.28CNYUpdated Aug 21, 202652-Week High
337.20CNYUpdated Aug 21, 202652-Week Change
-6.09%vs all stocks
Beta
-0.3800xvs all stocks
50-Day MA
204.48CNYUpdated Aug 21, 2026200-Day MA
232.07CNYUpdated Aug 21, 2026Avg 10-Day Volume
1.54MSharesUpdated Aug 21, 2026Avg 30-Day Volume
1.82MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
6.13CNYUpdated Aug 21, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 37.5%, higher than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: 0.38Industry median: 0.07Industry P95: 0.37Peers compared: 59.00
Profit margin is 31.8%, higher than 95% of its Medical Devices peers (median 3.6%)Significant
Profit margin: 0.32Industry median: 0.04Industry P95: 0.31Peers compared: 59.00
Return on equity is 29.7%, higher than 95% of its Medical Devices peers (median 2.8%)Significant
Return on equity: 0.30Industry median: 0.03Industry P95: 0.18Peers compared: 59.00
Return on assets is 18%, higher than 95% of its Medical Devices peers (median 2%)Significant
Return on assets: 0.18Industry median: 0.02Industry P95: 0.16Peers compared: 59.00
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.71
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $5.55B, above the global median of $1.15BNotable
Market cap (USD): 5,545,832,242.949Global Median: 1,146,734,693.424
Levered free cash flow is $54.7M, above the global median of $16.24MNotable
Levered free cash flow (USD): 54,696,713.404Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Travere Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Classys Inc.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Pharma Research Products Co., Ltd
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Shanghai Bochuan Electronic Co., Ltd.
11 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels